Fcγ-Receptor IIIA Polymorphism p.158F Has No Negative Predictive Impact on Rituximab Therapy with and without Sequential Chemotherapy in CD20-Positive Posttransplant Lymphoproliferative Disorder

Table 2

Frequency of FcγRIIIA p.V158F genotypes and alleles in healthy controls and PTLD patients.

Genotype	Controls	PTLD	𝑃
FcγRIIIA p.158 V/V homozygote	9 (8%)	11 (44%)	<0.0001
FcγRIIIA p.158 V/F heterozygote	50 (48%)	11 (44%)
FcγRIIIA p.158 F/F homozygote	46 (44%)	3 (12%)